Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

U.S. health officials have paused the distribution of two Eli Lilly & Co. Covid-19 monoclonal antibody treatments because of data showing they aren't effective against virus variants that are becoming increasingly common across the country.

The Wall Street Journal: Eli Lilly COVID-19 antibody drug shipments paused over variant concerns

Eli Lilly (LLY) is developing donanemab in a phase III study and plans to file a regulatory application seeking accelerated approval for the candidate as a treatment for AD in 2021.

Lilly's (LLY) AD Candidate Gets Breakthrough Therapy Status

INDIANAPOLIS, June 25, 2021 /PRNewswire/ -- Tirzepatide led to superior A1C and body weight reductions from baseline compared to injectable semaglutide 1 mg in 40-week results from Eli Lilly and Company's (NYSE: LLY) SURPASS-2 clinical trial, which were simultaneously published today in The New England Journal of Medicine (NEJM) 1 and presented in a late breaking poster presentation during the American Diabetes Association's® (ADA) 81st Scientific Sessions®2. These results, which will also be featured during an ADA-sponsored symposium on Tuesday, June 29, showed that all three tirzepatide doses achieved greater A1C and weight reductions compared to semaglutide.

Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes

Luminar Technologies

Find out what you need to know about all-time highs for stocks.

These 2 Key Themes Are Driving the Stock Market to Record Highs

Apple

Roku

Take-Two Interactive Software

Hydrofarm Holdings Group

Lear

Newell Brands

Procter & Gamble

Public Storage

Sierra Wireless

Halfway through Thursday's trading session stocks are higher following a back and forth Wednesday where the Nasdaq managed to close at an all-time high while all of the other major indices posted small gains.

Apple, Lilly, Take-Two Interactive, Roku and More Thursday Afternoon Analyst Research Calls

Goldman Sachs said Eli Lilly's decision to seek accelerated approval for donanemab was ahead of its expectations.

Eli Lilly jumps 10% after it says it will seek approval for its Alzheimer's drug following designation as a breakthrough therapy by the FDA

The company's promising Alzheimer's disease drug won FDA Breakthrough Therapy designation.

Why Eli Lilly Stock Is Soaring Today

Eli Lilly (LLY) stock is soaring higher on Thursday following news of a decision from the FDA for its new Alzheimer's drug. The post LLY Stock: The Alzheimer's Drug News Sending Eli Lilly Higher Today appeared first on InvestorPlace.

LLY Stock: The Alzheimer's Drug News Sending Eli Lilly Higher Today

INDIANAPOLIS, June 24, 2021 /PRNewswire/ -- In honor of the 100th anniversary of the discovery of insulin, Eli Lilly and Company (NYSE: LLY) today launched the Leonard Award to recognize diverse champions dedicated to advancing diabetes management through innovative thinking and novel approaches. Nominations are being accepted now until August 31, 2021 at Lilly.com/LeonardAward.

Lilly announces call for Leonard Award nominations as part of global initiative celebrating 100 years of insulin

INDIANAPOLIS, June 24, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's (NYSE: LLY) investigational antibody therapy for Alzheimer's disease (AD). The Breakthrough Therapy designation aims to expedite the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over already available therapies that have received full FDA approval.

Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease

Biogen

BioMarin Pharmaceutical

Ultragenyx Pharmaceutical

Roche Holding AG

FDA approval of Biogen's Aduhelm for Alzheimer's should be broadly supportive of biotechnology and pharmaceutical stocks as it signals the agency is willing to be flexible to make important drugs. The rerating of Biogen shares following the FDA decision demonstrates the potential of innovation in the biopharmaceutical industry to generate significant alpha for investors.

Alzheimer's Approval Validates Biopharmaceutical Innovation

One is Biogen's partner. The other is a potential rival.

2 Stocks That Could Be Winners in Alzheimer's Disease Along With Biogen

General Electric

Microsoft

Twilio

Microsoft, Twilio, Eli Lilly and General Electric were our top stock trades for Monday. Let's look at how the charts are setting up now.

4 Top Stock Trades for Monday: MSFT, TWLO, LLY, GE

Pfizer

We think that Pfizer currently is a better pick compared to Eli Lilly & Company. PFE stock trades at about 5x trailing revenues, compared to around 8x for LLY.

Is Pfizer Stock A Better Bet Compared To Eli Lilly?

INDIANAPOLIS, June 17, 2021 /PRNewswire/ -- Based on results from a large population-based survey, it is estimated that approximately half of people with migraine hesitate to seek care for a variety of reasons, and even fewer receive a diagnosis and take the treatment they need.1,2,3 To help address these important unmet needs in migraine care, Eli Lilly and Company (NYSE: LLY) launched Think Talk Treat Migraine™, a new initiative to empower people living with migraine and their primary care providers to recognize key symptoms of migraine and have better conversations about the disease that can lead to proper diagnosis and treatment. The initiative is currently in pilot stage – available in four metropolitan areas – Hartford/New Haven (Connecticut), Raleigh/Durham (North Carolina), Indianapolis (Indiana) and Denver (Colorado) – and provides people living with migraine and their healthcare providers with simple resources to think about, talk about and treat migraine.

Lilly Launches Think Talk Treat Migraine™ to Help Improve Diagnosis and Treatment of Migraine

Caterpillar

Cleveland-Cliffs

Chevron

Dow Inc

Goldman Sachs

Turtle Beach

Pioneer Natural Resources

Snap

Vertex Pharmaceuticals

Exxon Mobil

All the major indexes pulled back on Tuesday, with the Nasdaq leading the charge. Despite this, crude oil jumped back above $72 a barrel, and Bitcoin was fairly stagnant at $40,000.

Jim Cramer Has a Closer Look at Fed Policy, Energy Stocks, Snap and More

Biohaven Pharmaceutical Hld

Eli Lilly And Co (NYSE: LLY) will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN) Nurtec ODT (rimegepant) orally disintegrating tablet (ODT) patients take every other day. Enrolling will start later this year.

Eli Lilly To Test Injectable Migraine Med Against Biohaven's Oral Nurtec In Head-To-Head Study

INDIANAPOLIS, June 15, 2021 /PRNewswire/ -- To advance the science of migraine treatment and aid the understanding of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) compared to oral CGRP receptor antagonists in the prevention of migraine, Eli Lilly and Company (NYSE: LLY) will be conducting a head-to-head study comparing once-monthly injectable Emgality ® (galcanezumab-gnlm) with Nurtec ® ODT (rimegepant), an orally disintegrating tablet patients take every other day. CGRP is a protein in the brain thought to play a key role in migraine.

Lilly Announces Head-to-Head Study Comparing Once-Monthly Emgality® with Every-Other-Day Nurtec® ODT for the Preventive Treatment of Migraine

INDIANAPOLIS, June 14, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Biopharma Strategy Series – Biopharma's Next Decade: Views from the Top on Global Strategy and Innovation – on Friday, June 18, 2021. Daniel Skovronsky, M.D.

Lilly to Participate in Guggenheim Biopharma Strategy Series

Eli Lilly and Co (NYSE: LLY) revealed last month that the U.S. Department of Justice (DOJ) issued a subpoena into its manufacturing facility in Branchburg, New Jersey, but the company has already finished its independent investigation and concluded the company didn't make false statements to the FDA, Reuters reports. In the internal memo, the company denied allegations that it made any false statements to the FDA.

Eli Lilly's Internal Probe Clears Its COVID-19 Drug Plant; Memo Says Company Did Not Make False Statements: Reuters

INDIANAPOLIS, June 11, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a webcast on Thursday, July 1, 2021 to discuss the company's diabetes portfolio and its presentations at the American Diabetes Association's Virtual 81st Scientific Sessions. The webcast will begin at 10:00 a.m.

Lilly Announces Webcast to Provide Diabetes Portfolio Update at ADA

Prothena

The FDA's approval of Biogen's Aduhelm in treating Alzheimer's disease boosted all three stocks.

Why Biogen, Lilly, and Prothena Stocks Soared This Week

A week before Eli Lilly disclosed to regulators that the U.S. Justice Department was investigating its New Jersey factory, the drugmaker told employees that its own inquiry, led by an outside law firm, found no evidence of wrongdoing there, according to a company memo reviewed by Reuters.

Exclusive: Eli Lilly memo says firm did not make false statements to FDA

Eli Lilly And Co. (NYSE:LLY) shares are up nearly 12% this week after the Food and Drug Administration (FDA) approved Biogen Inc.'s (NASDAQ:BIIB) Alzheimer's drug, aducanumab marketed under the brand name Aduhelm. Now, analysts think the FDA's approval of aducanumab lowers the bar for Alzheimer's drug approvals.

Eli Lilly stock spiked after Biogen's Aduhelm approval: here is why

Annovis Bio

Arvinas Inc

Anavex Life Sciences

Virtus LifeSci Biotech Clinical Trials ETF

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

Loncar Cancer Immunotherapy ETF

Denali Therapeutics

First Trust NYSE Arca Biotechnology Index Fund

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector.

News for Eli Lilly Stock (LLY)